C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix speaks to Thomas Warner from Proactive after releasing half-year results for the six months ending 31 January 2023.
Dix gives his highlights from the interim results before turning his focus to what he describes as a “slight pivot” to anti-inflammatory treatments.
C4X has a portfolio of anti-inflammatory targets, including a molecule for COPD, and four or five new anti-inflammatory targets in the pipeline, which will be revealed in due course.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.